Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lenalidomide plus chemoradiotherapy in advanced nasopharyngeal carcinoma
ChiCTR2000035365Phase 4Not yet recruiting
- Sponsor
- Guigang People's Hospital
- Start
- Aug 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in nasopharyngeal carcinoma (NPC) comparing Lenalidomide + chemoradiotherapy with Placebo + chemoradiotherapy (2 arms). Primary endpoints: Progression-free survival, Overall survival and 7 more. Planned start Aug 2020; status: not yet recruiting.
02
Drugs
lenalidomide
03
Conditions
nasopharyngeal carcinoma (NPC)
Beyond the preview
Go deeper on ChiCTR2000035365.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000035365.